Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData, Phase II drugs for Chronic Urticaria Or Hives have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tezepelumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tezepelumab overview
Tezepelumab-ekko (Tezspire) is a first-in-class human monoclonal antibody immunoglobulin G2λ (IgG2λ) produced by recombinant DNA technology. It is formulated as solution for subcutaneous route of administration. Tezspire is indicated for the add-on maintenance treatment of adults, adolescents and pediatric patients aged 12 years and older with severe asthma.
Tezepelumab (AMG-157, MEDI-9929) is under development for the treatment of severe chronic rhinosinusitis with nasal polyposis, chronic spontaneous urticaria, severe uncontrolled asthma, eosinophilic granulomatosis with polyangiitis, chronic obstructive pulmonary disease, eosinophilic esophagitis, peanut allergy and cat allergy. The therapeutic candidate is administered intravenously and subcutaneously in the form of suspension and solution. AMG-157 is a fully human monoclonal antibody targeting the interaction of thymic stromal lymphopoietin (TSLP) with TSLP receptors. It was also under development for allergic asthma and atopic dermatitis.
Amgen overview
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Tezepelumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
